Public Health Advisory: Gadolinium Containing Contrast Agents for Magnetic Resonance Imaging: Omniscan, OptiMARK, Magnevest, Prohance and Multihance. US Food and Drug Administration, Centre for Drug Evaluation and Research.
www.fda.gov/cder/advisory/gadolinium.agents.htm

has been cited by the following article:

• TITLE: Comparison of Magnetic Resonance Urography (MRU) with Intravenous Pyelography (IVP) in Evaluation of Patients with Hydronephrosis on Ultrasonography Due to Pelvi-Ureteric Junction Obstruction

  AUTHORS: Gulzar Ahmad Bhat, Tarooq Ahmad Reshi, Asiya Rashid

  KEYWORDS: USG (Ultrasonography), MRU (Magnetic Resonance Imaging), IVU (Intravenous Urography)

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.7 No.5, May 31, 2016

  ABSTRACT: The objective of this study was to compare Magnetic Resonance Urography (MRU) with Intravenous Pyelography (IVP) in evaluation of patients with hydronephrosis on ultrasonography. 49 patients of hydronephrosis on USG were enrolled for the study from Jan. 2011 to Dec. 2012. All patients under went Intravenous Urography (IVU). MRU was done to determine the anatomical details and function of each renal unit. MRU was performed on a 1.5 tesla unit (Magneton Avento; Siemens, Erlangen, Germany). Static T2-weighted Magnetic Resonance Urography (MRU) was performed by using a standard fast spin echo technique. Dynamic study was performed after injecting intravenous diuretic followed by Gadolinium contrast media. Morphological results of MRU were compared with IVU. The anatomical findings were compared with operative findings. Stastical analysis was performed and data expressed as mean ± SD. MRU showed PUJ obstruction in 41 out of 45 patients (91.1%). We concluded that MRU can provide complete diagnostic evaluation of entire urinary tract in a single session and has potential to replace IVP.